Lexaria Bioscience Corporation (NASDAQ:LEXX) announced results from its Phase Ib study evaluating multiple GLP-1 agonists in combination with DehydraTECH (DHT). The study met its primary endpoint with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results